Developing Drugs for Heart Failure With Reduced Ejection Fraction: What Have We Learned From Clinical Trials?

There remains a large unmet need for new therapies in the treatment of heart failure with reduced ejection fraction (HFrEF). In the early drug development phase, the therapeutic potential of a drug is not yet fully understood and trial endpoints other than mortality are needed to guide drug development decisions. While a true surrogate marker for mortality in heart failure (HF) remains elusive, the successes and failures of previous trials can reveal markers that support clinical Go/NoGo decisions.

• Publication year

  2018

• Venue

  Clinical pharmacology and therapy

• Publication date

  2018-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cpt.1010PMID 29315510PMCID 5947521
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence

  2017cited by this paper
• Systematic review and meta-analysis.

  2017cited by this paper
• Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction

  2016cited by this paper
• Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure.

  2016cited by this paper
• 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

  2016cited by this paper
• Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial.

  2015cited by this paper
• State of the Art: Newer biomarkers in heart failure

  2015cited by this paper
• The Effect of inotropes and vasopressors on mortality: a meta-analysis of randomized clinical trials.

  2015cited by this paper
• Heart Failure With Preserved Ejection Fraction: What Is in a Name?

  2015cited by this paper
• Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure

  2015cited by this paper
• Novel drug targets in clinical development for heart failure

  2014cited by this paper
• Angiotensin-neprilysin inhibition versus enalapril in heart failure.

  2014influential reference
• A novel approach for establishing cardiovascular drug efficacy

  2014cited by this paper
• Elevated resting heart rate, physical fitness and all-cause mortality: a 16-year follow-up in the Copenhagen Male Study

  2013cited by this paper
• 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

  2013cited by this paper
• Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure.

  2013cited by this paper
• Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure.

  2013cited by this paper
• Additional use of an aldosterone antagonist in patients with mild to moderate chronic heart failure: a systematic review and meta‐analysis

  2013cited by this paper
• 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

  2013influential reference
• Heart failure–associated hospitalizations in the United States.

  2013cited by this paper
• The Use of Biomarkers in the Patient with Heart Failure

  2013cited by this paper
• 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.

  2013cited by this paper
• Epidemiology of Heart Failure

  2013influential reference
• Aldosterone antagonists improve ejection fraction and functional capacity independently of functional class: a meta-analysis of randomised controlled trials

  2012cited by this paper
• The role of natriuretic peptide testing in guiding chronic heart failure management: review of available data and recommendations for use.

  2012cited by this paper
• Effect of Nesiritide in Patients with Acute Decompensated Heart Failure

  2012cited by this paper
• Heart failure--does it matter whether LVEF is reduced?

  2012influential reference
• Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes

  2012cited by this paper
• Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies*

  2012cited by this paper
• Heart failure with a preserved ejection fraction: what is in a name?

  2011cited by this paper
• Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease.

  2011cited by this paper
• Neuroendocrine activation as a target of modern chronic heart failure pharmacotherapy.

  2011cited by this paper
• What are the costs of heart failure?

  2011cited by this paper
• Effect of nesiritide in patients with acute decompensated heart failure.

  2011cited by this paper
• Natriuretic peptide testing in heart failure.

  2011cited by this paper
• Long-term survival of cancer patients compared to heart failure and stroke: A systematic review

  2010cited by this paper
• Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.

  2010cited by this paper
• Newer biomarkers in heart failure.

  2009cited by this paper
• Profiles of serial changes in cardiac troponin T concentrations and outcome in ambulatory patients with chronic heart failure.

  2009cited by this paper
• Effect of Beta-blockade and ACE Inhibition on B-type Natriuretic Peptides in Stable Patients with Systolic Heart Failure

  2008cited by this paper
• Endothelin: 20 years from discovery to therapy.

  2008cited by this paper
• Telmisartan, ramipril, or both in patients at high risk for vascular events.

  2008cited by this paper
• Safety and efficacy of outpatient nesiritide in patients with advanced heart failure: results of the Second Follow-Up Serial Infusions of Nesiritide (FUSION II) trial.

  2008cited by this paper
• A Meta-analysis of Randomized Clinical Trials

  2008cited by this paper
• Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials.

  2007cited by this paper
• Effects of aldosterone receptor blockade in patients with mild–moderate heart failure taking a beta‐blocker

  2007cited by this paper
• Prognostic importance of plasma NT‐pro BNP in chronic heart failure in patients treated with a β‐blocker: Results from the Carvedilol Or Metoprolol European Trial (COMET) trial

  2007cited by this paper
• Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction.

  2007cited by this paper
• Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.

  2007cited by this paper
• Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial.

  2007cited by this paper
• Mechanism-Based Pharmacokinetic–Pharmacodynamic Modeling—A New Classification of Biomarkers

  2005cited by this paper
• NT‐proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT‐proBNP substudy

  2004cited by this paper
• Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment

  2004cited by this paper
• Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial.

  2004cited by this paper
• Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.

  2004cited by this paper
• Clinical biomarkers in drug discovery and development

  2003cited by this paper
• Heart failure/transplant: abstractEffects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT)☆

  2003cited by this paper
• Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure.

  2003cited by this paper
• Effects of Valsartan on Circulating Brain Natriuretic Peptide and Norepinephrine in Symptomatic Chronic Heart Failure: The Valsartan Heart Failure Trial (Val-HeFT)

  2002cited by this paper
• The impossible task of developing a new treatment for heart failure.

  2002cited by this paper
• Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy.

  2002cited by this paper
• Recent heart failure trials of neurohormonal modulation (OVERTURE and ENABLE): approaching the asymptote of efficacy?

  2002cited by this paper
• Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure.

  2001cited by this paper
• Acute Hemodynamic Effects of Conivaptan, a Dual V1A and V2 Vasopressin Receptor Antagonist, in Patients With Advanced Heart Failure

  2001cited by this paper
• A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.

  2001cited by this paper
• Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction.

  2001cited by this paper
• Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial.

  2000cited by this paper
• Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy : the randomized evaluation of strategies for left ventricular dysfunction pilot study.

  2000cited by this paper
• A DOSE-DEPENDENT INCREASE IN MORTALITY WITH VESNARINONE AMONG PATIENTS WITH SEVERE HEART FAILURE

  2000cited by this paper
• Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure.

  2000cited by this paper
• A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators.

  1999cited by this paper
• Valsartan in heart failure trial (Val-HeFT)

  1998cited by this paper
• Meta-analyses of randomised controlled trials.

  1997cited by this paper
• A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST).

  1997cited by this paper
• Reverse remodeling in heart failure with intensification of vasodilator therapy

  1997cited by this paper
• Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial.

  1996cited by this paper
• Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.

  1996cited by this paper
• Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.

  1995cited by this paper
• Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure

  1995cited by this paper
• Electrophysiologic and proarrhythmic effects of intravenous inotropic agents.

  1995cited by this paper
• Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure.

  1995influential reference
• Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study.

  1994cited by this paper
• Validity of the Minnesota Living with Heart Failure questionnaire as a measure of therapeutic response to enalapril or placebo.

  1993cited by this paper
• Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. SOLVD Investigators.

  1993cited by this paper
• Prediction of Mortality and Morbidity With a 6-Minute Walk Test in Patients With Left Ventricular Dysfunction

  1993cited by this paper
• Prognostic Significance of Serial Changes in Left Ventricular Ejection Fraction in Patients With Congestive Heart Failure

  1993cited by this paper
• Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.

  1992cited by this paper
• A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.

  1991cited by this paper
• Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group.

  1991cited by this paper
• A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure.

  1989cited by this paper
• Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

  1988cited by this paper
• Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

  1987cited by this paper
• Milrinone in congestive heart failure: acute and chronic hemodynamic and clinical evaluation.

  1985cited by this paper
• Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial.

  1985cited by this paper
• Antihypertensive and metabolic effects of a new converting enzyme inhibitor, enalapril

  1983cited by this paper
• Cardiocirculatory dynamics in the normal and failing heart.

  1981cited by this paper
• randomised double blind placebo controlled trial

  year unknowncited by this paper

• NATRIURETIC PEPTIDES – A VALUABLE TARGET IN THE TREATMENT OF HEART FAILURE

  2025cites this paper
• Omecamtiv Mecarbil in the treatment of heart failure: the past, the present, and the future

  2024cites this paper
• Differences in ejection fraction as inclusion criterion in randomized controlled trials among patients with heart failure with reduced ejection fraction: a systematic review

  2022cites this paper
• Evaluation of utilised doses of Heart Failure (HF) medications between genders and its association with clinical status among Heart Failure (HF) patients at hospital Serdang

  2022cites this paper
• Action of iron chelator on intramyocardial hemorrhage and cardiac remodeling following acute myocardial infarction

  2020cites this paper
• DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure

  2020cites this paper
• Nonpharmacologic Treatment for Heart Failure

  2020cites this paper
• Prognostic Value of the Six-Minute Walk Test in Heart Failure

  2020cites this paper